TIDMSN.
RNS Number : 2632E
Smith & Nephew Plc
09 March 2022
SMITH & NEPHEW PLC
9 March 2022
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE
REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY
PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND
PERSONS CLOSELY ASSOCIATED WITH THEM.
1. VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2010 AND 2020
On 7 March 2022, the following awards of US$0.20 ordinary shares
(the "Shares") in Smith & Nephew plc (the "Company") vested
under the Smith & Nephew Global Share Plan 2010 and 2020.
i. FINAL VESTING ON 7 MARCH 2022 OF 2019 EQUITY INCENTIVE
PROGRAMME AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2010:
The awards were granted under the Global Share Plan 2010 on 7
March 2019. One third of the Shares vested on 7 March 2020, a
further third vested on 7 March 2021 and the final third vested on
7 March 2022. A number of Shares were sold to cover taxation
obligations arising on the vesting of the awards. The number of
Shares acquired includes the dividend equivalent Shares which
participants receive on vested Shares.
The following relates to individuals included in the below
notification:
Reason for the notification
Initial notification Initial notification
/Amendment
--------------------------------------------
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
--------------------------------------------
LEI 213800ZTMDN8S67S1H61
--------------------------------------------
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
Description of the Smith & Nephew plc ordinary shares of
financial instrument, USD 0.20 each
type of instrument
--------------------------------------------
Identification code ISIN: GB0009223206
--------------------------------------------
Nature of the transaction Final vesting of Equity Incentive Programme
awards granted on 7 March 2019 under
the Smith & Nephew Global Share Plan
2010.
--------------------------------------------
Date of Transaction 2022 - 03 - 07
--------------------------------------------
Place of Transaction London Stock Exchange (XLON)
--------------------------------------------
Total Ordinary
Share Holding
Total Ordinary as a % of
Share Holding the Company's
following ISC following
Name Aggregated the transaction the transaction
(Position) Status Price (GBP) Volume information * *
2,417
(of which
1,140
Helen Barraclough were sold 18,769.75378
(Group General and 1,277 N/A Single ordinary
Counsel) PDMR 12.011211 retained) Transaction shares 0.00212%
---------- ------------ --------------- ------------- ------------------- -----------------
Bradley Cannon 4,983
(President, (of which 81,825.17832
Orthopaedics, 1,688 ordinary
Sports Medicine were sold shares (including
& ENT and and 3,295 N/A Single 2,718.50860
Americas) PDMR 12.011211 retained) Transaction in ADS') 0.00924%
---------- ------------ --------------- ------------- ------------------- -----------------
2,486
Phil Cowdy (of which
(Chief Business 1,173
Development were sold 48,446.96621
& Corporate and 1,313 N/A Single ordinary
Affairs Officer) PDMR 12.011211 retained) Transaction shares 0.00547%
---------- ------------ --------------- ------------- ------------------- -----------------
4,724
(of which 109,689.00000
1,851 ordinary
Elga Lohler were sold shares (including
(Chief HR and 2,873 N/A Single 3,015.00000
Officer) PDMR 12.011211 retained) Transaction in ADS') 0.01239%
---------- ------------ --------------- ------------- ------------------- -----------------
4,274
(of which
Vasant Padmanabhan 1,587
(President were sold 67307.00000
Research and 2,687 N/A Single ordinary
& Development) PDMR 12.011211 retained) Transaction shares 0.00760%
---------- ------------ --------------- ------------- ------------------- -----------------
1,743
(of which
Susan Swabey 823 were 50,970.39347
(Company sold and N/A Single ordinary
Secretary) PDMR 12.011211 920 retained) Transaction shares 0.00576%
---------- ------------ --------------- ------------- ------------------- -----------------
* including those held by Persons Closely Associated with the
Director/PDMR. All figures in these columns are stated to 5 decimal
places where applicable.
ii. FINAL VESTING ON 7 MARCH 2022 OF SUPPLEMENTARY AWARDS
GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020 FOR THE
2019 PERFORMANCE SHARE PROGRAMME AWARDS:
The awards were granted under the Global Share Plan 2020 on 8
March 2021. A number of Shares were sold to cover taxation
obligations arising on the vesting of the awards.
The following relates to individuals included in the below
notification:
Reason for the notification
Initial notification Initial notification
/Amendment
-------------------------------------------------
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
-------------------------------------------------
LEI 213800ZTMDN8S67S1H61
-------------------------------------------------
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
Description of the Smith & Nephew plc ordinary shares of
financial instrument, USD 0.20 each
type of instrument
-------------------------------------------------
Identification code ISIN: GB0009223206
-------------------------------------------------
Nature of the transaction Final vesting on 7 March 2022 of Supplementary
Awards granted under the Smith & Nephew
Global Share Plan 2020 for the 2019 Performance
Share Programme awards .
-------------------------------------------------
Date of Transaction 2022 - 03 - 07
-------------------------------------------------
Place of Transaction London Stock Exchange (XLON)
-------------------------------------------------
Total Ordinary
Share Holding
Total Ordinary as a % of
Share Holding the Company's
following ISC following
Name Aggregated the transaction the transaction
(Position) Status Price (GBP) Volume information * *
3,013
(of which
1,422
Helen Barraclough were sold 20,360.75378
(Group General and 1,591 N/A Single ordinary
Counsel) PDMR 12.011211 retained) Transaction shares 0.00230%
---------- ------------ ----------- ------------- ------------------- -----------------
Bradley Cannon 7,696
(President, (of which 86,914.17832
Orthopaedics, 2,607 ordinary
Sports Medicine were sold shares (including
& ENT and and 5,089 N/A Single 2,718.50860
Americas) PDMR 12.011211 retained) Transaction in ADS') 0.00982%
---------- ------------ ----------- ------------- ------------------- -----------------
5,641
Phil Cowdy (of which
(Chief Business 2,661
Development were sold 51,426.96621
& Corporate and 2,980 N/A Single ordinary
Affairs Officer) PDMR 12.011211 retained) Transaction shares 0.00581%
---------- ------------ ----------- ------------- ------------------- -----------------
Simon Fraser
(President, 6,791
Advanced (of which
Wound Management 2,021
& Global were sold 15,433.59428
Commercial and 4,770 N/A Single ordinary
Operations) PDMR 12.011211 retained) Transaction shares 0.00174%
---------- ------------ ----------- ------------- ------------------- -----------------
6,680
(of which 113,743.00000
2,626 ordinary
Elga Lohler were sold shares (including
(Chief HR and 4,054 N/A Single 3,015.00000
Officer) PDMR 12.011211 retained) Transaction in ADS') 0.01285%
---------- ------------ ----------- ------------- ------------------- -----------------
6,595
(of which
Vasant Padmanabhan 2,449
(President were sold 71,453.00000
Research and 4,146 N/A Single ordinary
& Development) PDMR 12.011211 retained) Transaction shares 0.00807%
---------- ------------ ----------- ------------- ------------------- -----------------
2,446
(of which
1,154
Susan Swabey were sold 52,262.39347
(Company and 1,292 N/A Single ordinary
Secretary) PDMR 12.011211 retained) Transaction shares 0.00590%
---------- ------------ ----------- ------------- ------------------- -----------------
* including those held by Persons Closely Associated with the
Director/PDMR. All figures in these columns are stated to 5 decimal
places where applicable.
2. PHIL COWDY - SALE OF ORDINARY SHARES
Reason for the notification
Initial notification Initial notification
/Amendment
------------------------------------------
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
------------------------------------------
LEI 213800ZTMDN8S67S1H61
------------------------------------------
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
Description of the Smith & Nephew plc ordinary shares of USD
financial instrument, 0.20 each
type of instrument
------------------------------------------
Identification code ISIN: GB0009223206
------------------------------------------
Nature of the transaction Sale of ordinary shares.
------------------------------------------
Date of Transaction 2022 - 03 - 08
------------------------------------------
Place of Transaction London Stock Exchange (XLON)
------------------------------------------
Total Ordinary
Share Holding
Total Ordinary as a % of
Share Holding the Company's
following ISC following
Director Aggregated the transaction the transaction
Name (Position) / PDMR Price (GBP) Volume information * *
Phil Cowdy
(Chief Business
Development 47,133.96621
& Corporate N/A Single ordinary
Affairs Officer) PDMR 11.793781 4,293 Transaction shares 0.00532%
---------- ------------ ------- ------------- ----------------- -----------------
* including those held by Persons Closely Associated with the
Director/PDMR. All figures in these columns are stated to 5 decimal
places where applicable.
Sarah Carne
Deputy Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477100
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFEDVAIAIIF
(END) Dow Jones Newswires
March 09, 2022 13:01 ET (18:01 GMT)
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Mar 2023 a Mar 2024